FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
A new “one-stop shop” will be launched so that NHS hospital trusts can access the latest technologies more quickly. Products will be given an “innovator passport”, licensing them for use across the country.
Read more here.
In a study published in Nature Communications, a team of researchers at the University of California, Los Angeles (UCLA) reported an AI tool that virtually stains unlabeled tissue samples at a resolution far exceeding that of the input image—without the use of any…
Attendees
Sponsors and Exhibitors
Contact us